AQST (Aquestive Therapeutics) Margin of Safety % (DCF Dividends Based): N/A (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AQST Aquestive Therapeutics Inc AQST
49 GF Score
Price $5.16
GF Value $2.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Aquestive Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Aquestive Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

AQST vs TLRY, EOLS, IRWD: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aquestive Therapeutics Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.


AQST
49GF Score
Aquestive Therapeutics Inc AQST
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aquestive Therapeutics (AQST) Overvalued in 2026?

Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued. The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37. GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.

Key valuation signals for AQST:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aquestive Therapeutics Business Description

Address 30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score

Get the complete analysis for AQST

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.16
Price
$2.37
GF Value